Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GELATO: Carboplatin and Atezolizumab in Metastatic Lobular Breast Cancer
NCT03147040Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2017
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Invasive Lobular Carcinoma (ILC), sponsored by Netherlands Cancer Institute. Started Nov 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NCT03147040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147040.